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Abstract

METHCATHINONE ANALOGUE ACTIVITY AT THE HUMAN SEROTONIN TRANSPORTER
William Drake Varn, Master of Science in Physiology and Biophysics
A thesis submitted for the partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.
Virginia Commonwealth University School of Medicine, 2016
Director: Louis J. De Felice, Professor, Department of Physiology and Biophysics

In the last few years, there has been continued concern about synthetic drug abuse
in both the United States and worldwide. Small adjustments in drug compound structure
often allow synthetic drug makers to manufacture a legal product that can produce the
same highs as illegal counterparts. Unfortunately, this is happening faster than the
government can outlaw the drug compounds, and a wide variety of synthetics are now
appearing on the street. This study evaluated the effects on the human serotonin
transporter of six different 4-para substituted methcathinone compounds. Using a Xenopus
oocyte model, the efficacy of each MCAT analogue at hSERT was calculated by applying the
Hill equation to the oocyte data. This study suggests that volume, size, and steric bulk of
the compound may generally influence efficacy at hSERT in a direct manner, but that other
factors, like lipophilicity, may also play an important role in potency at the transporter.

X

Introduction

1.1 Solute Carrier 6 Family (SLC6), Monoamine Transporters

Neurological chemical substances called neurotransmitters are stored in neurons
and can be released into the neural synapse. Neurotransmitters cause a myriad of effects in
the adjacent neurons and in the presynaptic neuron. These electrochemical events involve
neurotransmitters moving through transporters or binding to receptor sites, further
propagating a reaction or signal. The human body uses many different chemical
compounds as neurotransmitters, including a group named the monoamines. The three
monoamines - dopamine, serotonin, and norepinephrine - are derived from aromatic amino
acids and contain a two-carbon chain attached to both an aromatic ring and one amino
group (Maisto, Galizo, Connors, 2007). The chemical structure of both dopamine and
serotonin can be seen in Figure 1, on page 4. The monoamine transporters (MATs) are
responsible for the uptake and reuptake of their specific monoamine neurotransmitters to
maintain homeostasis within the body (Manepalli et al., 2012).
The monoamine transporters belong to the solute carrier 6 (SLC6) gene family.
There are 350 solute carrier transporters divided into 55 specific families. SLC6
transporters include the neurotransmitter transporters for GABA and glycine as well as the
dopamine, serotonin, and norepinephrine transporters. The polar dipole moments of the
amine group make monoamine neurotransmitters lipophobic and therefore they cannot
1

cross lipid bilayer membranes without the assistance of transporters. The MATs derive the
energy to move monoamines against a gradient by coupling the electrochemical potential
difference, or cotransport, of extracellular sodium ions and possibly chloride ions. They are
therefore sodium dependent transporters and secondary active transporters. More
specifically, MATs and all SLC6 transporters are classified as neurotransmitter sodium
symporters because the coupled sodium ions move in the same direction, outside to inside
the membrane, as the monoamine neurotransmitters (Immadisetty and Madura, 2013).
The kinetics of neurotransmitter transporters follow the Michaelis-Menten equation with
max turnover rate between 1 and 20 substrate molecules per second and EC50 (KM) values
in the low micromolar range (Humphries, Wall, and Rudnick, 1994). The function of
chloride in the transport event is still unclear. Many still believe that either one or multiple
chloride ions are cotransported with the neurotransmitter substrate and sodium ions
(Humphries, Wall, and Rudnick, 1994), but there is no direct evidence to prove this theory.
Chloride has been proven necessary for serotonin molecule transport through hSERT, but it
may simply be binding at an allosteric site and not actually transported across the
membrane with sodium and serotonin (De Felice, 2016). More future experiments are
needed to truly understand chloride’s distinct role at the monoamine transporters.
Neurotransmitter transporters, including MATs, maintain neurotransmitter
homeostasis in neurons by uptake of neurotransmitter into postsynaptic neurons or
through reuptake back into the presynaptic neuron. The amount, or density, of
transporters in the membrane can be regulated by the cell through up and downregulation. Adding or removing transporters may modulate the rate at which
neurotransmitters are removed from the synapse allowing the cell to control neuronal
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activity directly. For this reason, the MATs have been and continue to be drug targets for
treatment of many diseases and addictions (Hediger et al., 2003).
All monoamine neurotransmitter transporters share the same unique basic
structure. Molecular cloning suggests that on average approximately 40% of the amino
acid structure belongs to all neurotransmitter transporters. The human dopamine and
serotonin transporters have one single isoform consisting of 617 and 630 amino acids,
respectively, in 12 transmembrane helices. Both transporters contain intracellular N- and
C-termini, a glycosylated loop between transmembrane helices III and IV, and a pair of Cys
residues within extracellular loop 2 forming a N-linked glycosylation site and an intraloop
disulfide bridge (Guastella et al., 1990). Due to instability, quantity, and purity difficulties,
protein crystallization of SLC6 transporters has been difficult (Immadisetty and Madura,
2013) and some prokaryotic transporter proteins are more stable. The most important of
these prokaryote transporters is the leucine transporter (LeuT) because it has shown vast
functional resemblance and sequence homology to SLC6 transporters. (Yamashita et al.
2005). Recently, X-ray crystallography of the human serotonin transporter bound to two
seperate antidepressants was published (Coleman, Green, and Gouaux, 2016). Their
experiments identified the central binding site between helices 1, 3, 6, 8, and 10. An
allosteric site was shown to modulate ligand binding at the central site (Coleman, Green,
and Gouaux, 2016). Due to the novelty of these findings and the vast amount of research
performed previously on the leucine transporter, further discussion of transporter
structure and function will focus on LeuT.

3

Figure 1.1 : The chemical structure of the SLC6 family monoamines dopamine and
serotonin along with an illustrated representation of a monoamine transporter. The
illustration also depicts the number of ions thought to travel across the membrane with the
monoamines. It is important to note that the role of the chloride ion is still unclear, and Clmay not actually be transported across the membrane (De Felice, 2016). (Above figure
borrowed from SCL6 Neurotransmitter Transporters: Structure, Function, and Regulation by
Kristensen et al., 2011.)
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1.2 The Leucine Transporter, Structure and Relevance to SLC6 Family

The thermophile bacteria Aquifex aeolicus possess the leucine transporter, and LeuT
shares 20-25% sequence identity with the MATs (Immadisetty and Madura, 2013). Its
resemblance has been extensively verified and structures of LeuT have been elucidated,
with and without substrates and with competitive and noncompetitive inhibitors. X-ray
crystallography of LeuT confirmed the 12 transmembrane helices with internal N- and Cterminus structure and confirmed individual properties of each transmembrane protein’s
intracellular and extracellular half. For example, the large second extracellular loop and its
multiple glycosylation sites seem to play a role in synthesis, trafficking, and stability (Hahn
and Blakely, 2007). LeuT also established the cylindrical shape of the helical protein
bundle with transmembrane protein 1 (TM1), TM3, TM6, and TM8 making up the inner
ring, forming a distinct central binding pocket (S1) for substrates. TM1, TM3, TM6, and
TM10 contain side chains that interact in a network to block the S1 binding pocket from
external media. The intracellular halves of TM1, TM6, and TM8 form the second half of the
gating region; a large tight protein network covering the S1 binding site on the intracellular
side. In order for a substrate to bind, these protein regions must undergo structural
rearrangement in a sequence of conformational states. These regions are consistent
throughout the SLC6 family, except for one glutamate replacing Asp404 in the serotonin
transporter (Yamashita et al., 2005; Kristensen et al. 2011).
The overall asymmetric LeuT structure, called the “5+5 inverted repeat”, is not
consistent with the structure of SLC6 transporters, but it is believed that LeuT’s central
binding site (S1) and sodium ion binding sites are equivalent to the corresponding sites
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within SLC6 transporters; the four-helix bundle comprising these sites shares 55-67%
sequence similarity. This discovery established the LeuT homology model for
neutrotransmitter transporters and has allowed reputable 3D models of human DAT and
SERT. The model does retain limitations; while the inner and outer ring regions are overall
analogous, the intra- and extra-cellular loop regions and the short N- and C- termini of
LeuT differ from the SLC6 counterparts (Yamashita et al., 2005; Kristensen et al. 2011).
The S1 pocket consists of two distinct regions. First, TM1 and TM6 form a polar
region that can contain the charged α-amino and α-carboxylate groups of the amino acid
substrate. These alpha groups form hydrogen bonds with available amide groups on TM1
and TM6. The second section of the S1 pocket consists of hydrophobic sections of TM1,
TM3, TM6, and TM8 in order to accommodate a substrate’s aliphatic hydrophobic side
chains. This second portion plays a large role in binding specificity of substrates in S1.
Molecular dynamics have suggested the presence of another binding site in LeuT,
the S2 binding site, within the solvent-accessible path from extracellular media to the S1
site and separated by an extracellular gate. Various LeuT inhibitors have been found
bound in the S2 site, preventing necessary conformational changes allowing substrate
movement to the intracellular side. It has thus been proposed that occupation, or possibly
a lack there of, in the S2 site is required to initiate conformational movement required for
substrate to enter the cell. The S2 site control of S1 alludes to a possible SLC6 transporter
inhibitor mechanism of action (Singh et al. 2007; Yamashita et al. 2005). The recently
published hSERT crystal structure studies by Coleman, Green, and Gouaux confirms the
notion of an allosteric site in hSERT. Using electron density mapping, the studies showed
citalopram bound in an allosteric site that is distinct in hSERT and not present in hDAT.
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Mutations to this allosteric site resulted in markedly decreased potency of citalopram
binding, but the resulting effects on substrate transport are still unclear (Coleman, Green,
and Goax, 2016). A structural representation of S1 and S2 can be seen in Figure 2, on page
9.
In addition to the S1 and S2 binding sites, there are also two sodium ion-binding
sites in LeuT. The two sites, Na1 and Na2, are both located within the S1 binding pocket.
The sodium bound in the N1 site interacts with the α-carboxyl group of the transporter
substrate and this is believed to be the first step towards translocation of both into the cell.
Both Na1 and Na2 serve to stabilize TM1 and TM6 in the presence of substrate by
organization with side-chain oxygens and backbone carbonyls, five for Na1 and eight for
Na2 as can be seen in Figure 3. The structure of SERT illustrates the conservation of
residues surrounding the sodium ion binding sites throughout the SLC6 transporter family,
because an Asp in monoamine transporters exchanged for Gly24 in LeuT is the only
structural difference between LeuT, DAT and SERT. It is less clear whether or not the Na2
site is structurally and functionally identical to LeuT and the SLC6 transporters. Five
different residues make up Na2 in LeuT, of which one is identical and three are very similar
in the SLC6 family. Multiple theories have been proposed about the roles of both the Na1
and Na2, but some human neurotransmitters only translocate one sodium ion and others
two. Only speculations can be made to the exact function of Na1 and Na2 due to
discrepancies across the SLC6 family regarding these sites, and a current lack of functional
data (Singh et al. 2007; Kristensen et al. 2011).
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Figure 1.2 (right) : A computer
generated illustration of the S1 and S2
binding pockets in LeuT. The different
transmembrane domains that
construct the binding pockets can also
be seen. The yellow spheres
represent a leucine within the main
substrate binding pocket.
(Above figure borrowed from
Kristensen et al., 2011.)

Figure 1.3 :
The leucine transporter’s Na1 and Na2, shown in purple, stabilize TM1 and TM6 by
organization with side-chain oxygens and backbone carbonyls; five for Na1 and eight for
Na2. (Figure 3 also borrowed from Kristensen et al. 2011).
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1.3 MAT Mechanism of Action - Alternating Access Model

The first model of transport mechanism was proposed in the late 1950s, then was
adjusted and named the “alternating access” model about a decade later. Supporters of the
alternating access theory believe that secondary active transporters have three main
conformational states. First, the substrate binding site is exposed to the external media.
Next, the binding site is internalized and blocked from all media. Finally, the binding site is
exposed to the internal media. This model suggests impermeable gates, or a gating like
action, on the external and internal sides that can be closed as the transporter transitions
through conformational states to move substrate into or out of the cell (Jardetzky, 1966;
Mitchell, 1990). Early research indicated multiple TM regions and residues undergo
conformational change and move positions, possibly substantiating the alternate access
model and making it the widely accepted basis for transport mechanism. The discovery of
LeuT’s stable nature for testing, structure, and relationship to the SCL6 family and
monoamine transporters has begun offering glimpses of various transporter
conformations. LeuT has been shown in the outward-facing conformation but not the
inward-facing conformation, though other prokaryotic transporters sharing LeuT’s ‘5+5
inverted repeat’ folding have been crystalized in both. For example, a sodiumbenzylhydantoin symporter (Mhp1), a carnitine-butyrobetaine aintiporter (CaiT), an
arginine-agmatine symporter (AdiC), an H+-coupled amino acid symporter (ApcT), and a
sodium-galactose symporter (vSGLT) all share the 5+5 repeat and have been crystalized in
multiple conformations. All five hail from five different transporter families, though this
apparent conservation of structure across transporters has corroborated the theory that
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the related SCL6 family of transporters operates by the same mechanisms (Forest and
Rudnick, 2009; Kristensen et al. 2011).
Multiple models of the alternating access transport theory have been proposed, and
each begins with the initial step of substrate binding in the S1 site. Experiments with LeuT
and competitive inhibitors indicate that once the substrate has entered through an
extracellular permeation pathway and bound to its proper site, a transition begins
(Malinauskaite et al., 2014; Stolzenberg et al., 2015). The substrate becomes completely
occluded in an intermediate step, thanks to external portions of TM1, TM3, TM6, TM8, TM2,
and TM10 rearranging to form the extracellular gate. Next, a pathway forms between the
inner ring portions of TM1, TM6, and TM8 so that the substrate can be released and diffuse
into the cell. The second step, transitioning to the intracellular pathway, requires much
more movement and translocation than the first step of just closing the extracellular gate.
How exactly this happens is unclear, but one theory states that TM1 and TM6 hinge in the
middle, allowing their unwound end segments to block extracellular and intracellular
media when appropriate (Malinauskaite et al., 2014; Stolzenberg et al., 2015; Billesbølle et
al., 2015). A contrasting model proposes a more inflexible rocking motion between the
outward and inward conformations due to TM1 and TM6 interacting with TM2 and TM7 in
an inelastic fashion. And still, another speculation involves TM1 and TM6 rearranging
counterclockwise with TM8. While there has been a recent surge in research on SCL6
transporters and monoamine transporters, a deficiency in protein dynamic experimental
data still presents issues correlating proposed structural mechanisms with actual
transporter function (Beuming et al., 2006).
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Figure 1.4 : A visual representation of the four possible conformations involved in the
alternating access model of substrate transport. Each conformation can change in one of
two ways, either releasing the substrate, or holding it within the binding pocket – one
theory of how the transporters employ a gating mechanism (Figure 4 borrowed with much
thanks from SCL6 Neurotransmitter Transporters: Structure, Function, and Regulation by
Kristensen et al., 2011). It is important to note that this model of transport would not
result in the currents seen in TEVC, and therefore there must be another mechanism of
transport acting instead, or along side, the alternating access model.
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1.4 MAT Mechanism of Action – Transporter Channels

As data and analysis of transporter action have improved, the partition between
active transporters and passive ion channels has begun to get cloudier. After the discovery
of co-transporters, many believed that electrodiffusion was not a sufficient mechanism for
concentrating against a gradient. These researchers and scientists thus presented
transporters in a more enzymatic scheme, based on radiolabeled uptake experiments,
giving rise to the alternating access model. The disagreeing group stuck to electrical
measures and experiments, creating a contrasting theory of electrodiffusion governed
channels as a mechanism for transporters. More recently developed experimental
methods, such as single channel patch clamp and the cloning of co-transporters, have
revealed that the true mechanism of transporters might be a combination of both ideas (De
Felice, 2004).
Dr. L. De Felice has proposed that co-transporters might actively follow the enzyme
theory, but under the correct conditions the transporter may open into a passive channel
mode. Co-transporters could act as channels while using flux coupling to drive secondary
activity. Flux coupling takes place when a channel is too narrow to allow the substrate and
ion to pass each other. If the ion flow down its gradient is dominant enough, it can force
the substrate against its own gradient (De Felice, 2004). Thanks to convincing experiments
beginning in the 1990s, the presence of a channel in transporters is well documented,
though the purpose and function of the channel is still unclear.
In a 2007 review paper, De Felice and Goswami made a compelling argument for the
presence of a channel in monoamine transporters. Dopamine and serotonin transporters
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generate a current because the membrane crossing substrates and sodium carry a positive
charge, which is only partially offset by chloride’s negative charge. The movement of all
three across the membrane creates a current that can be quantified by the equation:
I = Nνq
in which “I” is the current, “N” is the number of transporters, “ν” is the cycle rate, and “q” is
the net charge transferred with each cycle of the transporter. A single 5HT substrate
molecule has a +1 charge for the equation above (1 5HT+, 1 Na+, 1 Cl-). If one million
transporters operate in an alternating access like fashion at one cycle per second with a
transfer of +1 charge for each cycle, 0.16 pico-amps of current would be generated per
second (De Felice and Goswami, 2007). Flash photolysis and whole cell patch clamp
techniques have shown that the total current across the membrane due to serotonin
transporters alone falls in the hundreds of pico-amps (Bruns et al., 1993). This large
discrepancy clearly points to another mechanism taking place and a transporter channel
function could create the much greater current.
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1.5 Monoamine Transporters & Drugs

Despite our lack of molecular understanding of MATs’ functional mechanisms, drugs
have been used for years to manipulate these channels and neural activity. Currently there
are more than 30 drug compounds available that affect MATs. Many more have been
developed but not made it to market due to lack of efficacy or side effect consequences.
Two sets of drugs, the monoamine oxidase inhibitors (MAOIs) and tricyclic
antidepressants (TCAs), were discovered and used to treat patients as far back as the
1950s. These drugs are not specific and modulate multiple neurotransmitters. Neither are
first line medications today due to a myriad of side effects. Like the name suggests, the
MAOIs inhibit the monoamine oxidase enzyme, which breaks down monoamines in the
synaptic cleft. MAOIs affect dopamine, serotonin, and norepinephrine. A limited tyramine
diet is required, or MAOIs can cause hypertensive crisis. The tricyclic antidepressants were
discovered a few years after the MAOIs and were then implemented as first line treatment
for many years. TCAs primarily block reuptake of 5-HT and norepinephrine, but also block
muscarinic M1 receptors, histamine H1, and alpha-adrenergic receptors. This lack of
specificity causes dose related side effects like cardiac effects, anticholinergic and
antihistamine effects, decreased seizure threshold, sexual disfunction, diaphoresis, and
tremor (Hirsch and Birnbaum, 2015 [1]). Despite the wide range of possible adverse
effects, many people still safely use tricyclics today.
Currently, selective serotonin reuptake inhibitors (SSRIs) are more typically given
to treat depression or other psychiatric disorders. The FDA approved fluoxetine in 1987 as
the first SSRI safe for treatment and there are now 6 different commonly prescribed SSRIs.
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Besides depression, SSRIs can alleviate panic disorders, obsessive-compulsive disorders,
PTSD, general and social anxiety, many eating disorders, and premenstrual dysphoric
disorder. It is believed that SSRIs inhibit the cytochrome P450 hepatic enzyme which
metabolizes many substances, and therefore adverse drug interactions are possible when
taking SSRIs. SSRIs reach peak plasma levels within eight hours of being absorbed by the
GI tract and are thought to reduce 5-HT reuptake activity by 60 to 80 percent.
Unfortunately, the full therapeutic effects of SSRIs are not typically realized for 3 to 8
weeks after initial consumption. Many attribute this to SSRIs’ downstream effects and slow
increase in neuroprotective proteins (Hirsch and Birbaum, 2015 [2]).
More recent drug discovery has produced a selective dopamine reuptake inhibitor
called bupropion, dual-acting inhibitors like selective serotonin and norepinephrine
reuptake inhibitors (SNRIs, ex: duloxetine), dopamine and norepinephrine inhibitors (ex:
nomifensine), and compounds that inhibit all three monoamine transporters (ex:
tesofensine). Cocaine is also a nonselective reuptake inhibitor at all three transporters.
Cocaine is most commonly associated with dopamine because it is more efficacious at
hDAT than hSERT, and because it is believed that DAT causes addiction properties (Carroll,
2003; Jin et al., 2008). Most illegal drugs elicit some degree of modulation at each
monoamine transporter. The relevant drugs are discussed below in the individual DAT and
SERT chapters.
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1.6 Human Serotonin Transporters (hSERT)

Serotonin, or 5-hydroxytryptamine (5-HT), transporters are best known for their
effects in the central nervous system, but these transporters are also located in the enteric
nervous system, in specialized neuronal cells, and in placental syncitiotrophoblasts
(Blakely et al., 1998). Outside of the CNS, serotonin plays a role in regulating
cardiovascular function, bowel motility, energy balance and food intake, endocrine
function, and some genitourinary effects. At least 15 different serotonin transporters have
been identified and grouped into seven families based on signaling mechanisms. This
plethora of receptors in various locations explains why sometimes side affects like
diabetes, metabolic syndromes, and valvular heart disease can occur with serotonergic
drugs (Berger et al., 2009).
All brain regions express multiple serotonin receptors, and even individual neurons
can express multiple 5-HT receptors. Serotonin, an indolamine neurotransmitter released
from neurons originating in the raphe nuclei, modifies anger, aggression, appetite,
attention, mood, perception, reward, and sexuality. Each serotonin receptor subtype can
affect one or many different brain processes (Berger et al., 2009). 5-HT plays a role in
many related mental illnesses including depression, obsessive-compulsive disorders,
anxiety, eating disorders, autism, schizophrenia, and alcohol abuse. Many attempts have
been made to link SERT, or a lack of 5-HT and SERT, to impulsivity and the diseases listed
above. At this time no conclusive data has been shown (Hahn and Blakely, 2007).
The human serotonin transporter is encoded by the SCL6A4 gene. SERT knockout
mice have been engineered by altering this gene. The knockout mice display an increase in
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extracellular 5-HT and a decrease in 5-HT tissue content, despite the overall level of 5-HT
biosynthesis remaining constant (Bengel et al., 1998). These results suggest that the
transporter is, in fact, the main mechanism by which the body removes released 5-HT and
by which cells reclaim 5-HT for intracellular stores. These results have also been seen
when 5-HT reuptake inhibitors are administered during early development, linking
development, 5-HT homeostasis, and adult anxiety-related behavior (Bengel et al., 1998).
Variations in the promoter region, located 1 kilobase upstream, modify human SERT
expression. There are two polymorphisms defined by the presence or absence of a 44-base
pair group in the promoter region: the short allele and the long allele. Two singlenucleotide polymorphisms have been shown to slightly modify transcriptional activity, but
transcriptional activity is mainly determined by short versus long allele, with the short
having a lower transcriptional activity. Some data suggest that humans who possess the
short allele are more predisposed to depression in response to stress, and are more likely
to demonstrate neuropsychiatric conditions [ex: autism, OCD, eating disorders] and
anxiety-related personality traits (Kristensen et al, 2011; Hahn and Blakely, 2007). Other
preliminary data suggest that the short allele limits the affects of selective serotonin
reuptake inhibitors (SSRIs) in depressed patients due to the lack of SERT. The longer allele
causes proper transcription of SERT, but may predispose to hypertension through an
unknown mechanism of SERT located on blood platelet cells (Hahn and Blakely, 2007;
Eddahibi et al., 2001).
In addition to the long and short allele, other variants have been found. The I425V
variant is associated with obsessive-compulsive personality disorder and, interestingly,
increases uptake compared to wild-type. It has been proposed that either altered surface
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expression or enhanced intrinsic transport capacity causes this difference in uptake ability
(Kilic et al., 2003; Prasad et al., 2005). Five different short-nucleotide polymorphisms
(SNPs) have been acknowledged in relation to autism. These SNPs cause mutations in the
coding region of the SERT gene and, similar to the I425V variant, result in an increase in
SERT expression and uptake levels. A third variant, the K201N variant, has increased
glycoslylation and has been shown to increase SERT expression levels by thirty percent
(Kristensen et al., 2011; Rasmussen et al., 2009).
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Mechanism

Drugs Involved

Increases Serotonin Formation

Tryptophan

Monoamine Transporter Substrates

Amphetamines (including
dextroamphetamine, methamphetamine)
MDMA (Ecstasy)
Amphetamine derivatives (including
fenfluramine, dexfenfluramine,
phentermine)
Levodopa, Carbidopa-levodopa (indirectly)

Monoamine Transporter Inhibitors

Cocaine
Selective Serotonin Reuptake Inhibitors
(SSRIs) (including citalopram,
escitalopram, fluoxetine, fluvoxamine,
paroxetine, sertraline)
Serotonin-Norepinephrine Reuptake
Inhibitors (SNRIs) (including
desvenlafaxine, duloxetine, milnacipran,
venlafaxine)
Dopamine-norepinephrine reuptake
inhibitors (including bupropion)
Serotonin modulators (including
nefazodone, trazodone, vilazodone)
Tricyclic Antidepressants (TCAs) (including
amitriptyline, amoxapine, clomipramine,
desipramine, doxepin, imipramine,
maprotiline, nortriptyline, protriptyline,
trimipramine)
St. John’s Wort (Hypericum perforatum)
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Monoamine Transporter Inhibitors
(Continued)

5-HT3 receptor antagonists (dolasetron,
granisetron, ondansetron, palonosetron)
Valproate
Sibutramine

Inhibits Serotonin Metabolism (inhibits
monoamine oxidase activity)

Monoamine oxidase inhibitors (MAOIs)
(including phenelzine, tranylcypromine,
isocarboxazid, moclobemide, selegiline,
rasagiline, linezolid, tedizolid, methylene
blue, procarbazine, Syrian rue)
Lorcaserin

Direct Serotonin Agonist

Buspirone
Triptans (including sumatriptan, rizatriptan,
others)
Ergot derivatives (including ergotamine,
methylergonovine)
Fentanyl
Lysergic acid diethylamide (LSD)

Increases Sensitivity of Postsynaptic
Serotonin Receptor

Lithium

Table 1.5 : List of mechanisms affecting serotonin and SERT, and also the drugs that elicit
each mechanism.
(adapted from UpToDate.com “Examples of drugs that can precipitate serotonin syndrome”
http://www.uptodate.com/contents/image?imageKey=EM/64604&topicKey=PSYCH%2F1
4675&source=outline_link&search=ssri&selectedTitle=1~150&utdPopup=true )
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1.7 Xenopus Oocytes and RNA Expression

The Xenopus laevis, or African clawed frog, originally populated areas south of the
Sahara desert along the African Rift Valley, but today are found all over the world in
stagnant pools and streams. This species of frog can live up to fifteen years and is sexually
mature ten to twelve months after birth. Each female can mate up to four times a year, and
mating is most common in spring and summer. They lay between five hundred and two
thousand spherical eggs at once, each 0.04 inch (0.1 cm) in diameter. Each female can
produce and lay up to 8,000 eggs a year, making the frogs and their eggs a viable,
inexpensive, and efficient research model for many experiments (nationalzoo.si.edu).
The Xenopus oocyte’s large size makes them easy to handle in electrophysiology
models under a microscope. The oocyte possesses a resting membrane potential between
-50 and -60 mV, due mainly to the permeability of K+ ions (nationalzoo.si.edu). After
fertilization occurs, the oocytes prepare for the upcoming developmental stages by
producing and storing organelles, enzymes, and proteins. Electrophysiology takes
advantage by influencing the oocyte to produce choice proteins of interest.
Human RNA cannot simply be injected into the oocyte and be expressed. The RNA
template must first be placed into a Xenopus oocyte compatible vector, so the cDNA of
SERT and DAT was subcloned into a pOTV vector, or Oocyte Transcription Vector.
Afterward, mRNA can be prepared in vitro from the cDNA and this RNA can be injected into
the oocyte. The human protein located within the pOTV will now be synthesized,
assembled, and targeted to the oocyte membrane (Miller and Zhou, 2000). Typically,
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between 107 – 1010 new proteins will be expressed in each cell’s membrane (Sigel, 2010).
A summary of the oocyte process can be seen in the figure below.

Figure 1.6 : A summary of the steps necessary to express membrane proteins in Xenopus
oocytes, beginning with nucleic acid extraction from tissue. It is worth noting that in our
synthetic cathinone experiments human MAT RNA was injected into the vegetal
hemisphere only, though microinjection into the animal hemisphere is also possible, as
shown (Figure borrowed from E. Sigel’s ‘Microinjection into Xenopus Oocytes’, 2010).
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1.8 Two-Electrode Voltage Clamp

The most common electrophysiological technique used with exogenous mRNA
expression in Xenopus oocytes is two-electrode voltage clamp, or TEVC. TEVC has provided
the majority of our ion channel property data and understanding. Two-electrode voltage
clamp permits the study of ion channels, or other electrogenic membrane proteins, by
controlling the oocyte membrane potential (VM). This technique can be used with voltagedependant ion channels, or with ligand-gated ion channels. In our case, the DAT and SERT
transporters are ligand gated transporters and TEVC tracks the electrical potential changes
across the membrane due to ion and substrate [neurotransmitter or drug] movement
(Guan et al., 2013).
The asymmetrical ion distribution across the cell membrane causes an
electrochemical gradient, and this difference gives rise to the membrane potential. This
gradient and potential are due to a host of ions, each of which demonstrate varying
permeability dependent upon the particular environmental conditions. The GoldmanHodgkin-Katz equation is pertinent to this research because it describes how ion
permeability and changes in the permeability change the overall membrane potential. In
order to use the equation one must assume that there is free diffusion across the
membrane, that the diffusion coefficient (DC) remains constant, and that the electrical field
within the membrane remains constant (Bierwirtz and Schwarz, 2014). If these conditions
are met, the Goldman-Hodgkin-Katz equation for Na+, K+, and Cl- can be given by:
EGHK = (RT/F) ln [(PNA[Na]out + PK[K]out + PCl[Cl]in) / (PNa[Na]in + PK[K]in + PCl[Cl]out)]
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where R is the universal gas constant, T is the absolute temperature, and F is the Faraday
constant.
The opening and closing of ion channels govern the resistance characteristics of the
cell membrane, and therefore current-voltage (IV) properties describe functions of the
transporters in the membrane (Bierwirtz and Schwarz, 2014). Two-electrode voltage
clamp employs two electrodes, both inserted into a large cell with low resistance (oocyte).
The first electrode injects a varying current, the command potential (VC), into the cell
maintaining a desired value; in this case it maintains the cell’s resting membrane potential
(VM) of approximately -60mV. The second electrode, the potential electrode, measures how
much current must be injected into the cell to keep the desired value (Guan et al., 2013).
Figure 6 below further displays the basic theory and workings of TEVC.
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Figure 1.7 : Conventional two-electrode voltage clamp (TEVC) on an oocyte (borrowed
from Guan et al., 2013). A1 is a voltage follower with high input impedance and low
resistance that monitors VM. A1’s output equals VM and is measured by the connected
clamping amplifier, A2. A2 compares the measured VM to VC, the voltage command signal,
which is applied to the other input terminal. ε is the current output of A2, which is a
current proportional to the difference between VM and VC. This current flows through the
current electrode, electrode 2, and into the cell. VM clamping is achieved when VM nears VC.
The current passing through electrode 2 counterbalances VM deviations and is therefore
measured as the membrane current (Guan et al., 2013).

25

1.9 Cathinone, Methcathinon, and Analogues

An underground market of synthetic psychoactive substances has emerged and
thriven within the last decade. The Unites States’ and European Union countries’ laws
prohibiting conventional illicit drugs drive many individuals to seek other legal substances
that produce the same effects. These new synthetic compounds are often synthesized by
clandestine chemists, but some can even be cooked by individuals with little chemistry
background. When made correctly, synthetics elicit the desired affects but they also are
often very toxic in higher doses. For example, synthetic cannabinoids or “spice”, activate
endocannabinoid receptors similar to cannabis, and synthetic cathinones or “bath salts”,
activate pathways similar to cocaine and amphetamines. When taken in excess, drugs such
as these can cause violent behaviors and many health problems including hallucinations,
agitation, psychosis and death (Baumann et al., 2014). Recently, a man in Florida
attempted to cash a check for 386 billion dollars, and another individual turned himself in
to police for “murdering his imaginary friend.” While these two stories could easily be
fabricated, the media suggested that both men ingested toxic amounts of bath salts prior to
these events. True or not, these are two of the many events associated with bath salt
intoxication pushing governments to outlaw known forms of these synthetic drugs.
Unfortunately, each new ban provokes the manufacture of similar chemical analogues in
hopes of legally achieving the same high.
The most widely publicized and horrific bath salt-associated incident involved a
man becoming cannibalistic during a drug induced psychotic break in Miami, Florida. This
event occurred in late 2010, around the time bath salts first began appearing as a substance
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of abuse. Toxicology screens were inconclusive for bath salts, but the man had consumed
multiple unknow pills found in his stomach post-mortem. Bath salt drugs can contain one
or multiple compounds that can potentially cause such mental instability. These
compounds are related to the naturally occurring β-keto amphetamine parent compound,
methcathinone (MCAT) (Baumann, et al. 2014). MCAT has been shown to have
psychostimulant properties (Schechter and Glennon, 1985), but most bath salt drugs
consist of a cocktail of cathinones and adulterants, including caffeine and lidocaine
(Zawilska and Wojcieszak, 2013). Besides methcathinone itself, there are three main
cathinones most often found in bath salts; mephedrone (4-methyl-N-methylcathinone, 4CH3 MCAT), methylone (3,4-methylenedioxy-N-methylcathinone), and MDPV (3,4methylenedioxypyrovalerone). The structure of each and their relation to methcathinone
can be seen below in Figure 7.
Synthetic cathinones behave by targeting monoamine transporters in the nervous
system to increase extracellular monoamine concentrations within neural synapses.
Synthetic cathinones, like other stimulant drugs that interact with monoamine
transporters, may cause neurotransmitter rise in one of two ways. First, they can act like
amphetamine by allowing greater neurotransmitter efflux, or an increased concentration of
substrate to enter the synaptic cleft. Second, bath salt compounds could act like cocaine by
blocking the transporters (Rothman and Baumann, 2003). The amphetamine-like
mechanism produces inward currents when performing two-electrode voltage clamp.
Cocaine-like drug mechanisms trigger the opposite signal, or a hyperpolarization on a twoelectrode voltage clamp plot (Baumann et al., 2014). These results have been shown in
other models as well, including HEK293 cells (Eshleman et al., 2013; Baumann et al., 2012).
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A synthetic cathinone’s selectivity for the dopamine transporter is a powerful
estimation of that particular drug’s behavioral effects. Selectivity for DAT transporters
results in high locomotor stimulation, while selectivity at SERT does not (Rothman and
Baumann, 2006). Methcathinone is mainly selective for DAT, while mephedrone and
methylone mirror the well-known illicit drug MDMA (3,4methylenedioxymethamphetamine, “molly”, “ecstasy”) by being reasonably nonselective at
all monoamine transporters. Specifically, mephedrone (4-CH3 MCAT) causes higher
serotonin release but less dopamine release than methcathinone (MCAT). Cathinone
analogues, that contain the same ring-structured backbone, have presented comparable
nonselective results at MATs (Baumann et al., 2012; De Felice et al., 2014).
The third main bath salt compound, MDPV, exhibits selectivity unlike the other two.
MDPV has been shown to be selective for DAT and norepinephrine transmitters, while
prompting little effect at SERT. MDPV is 50 times more potent of a blocker at DAT than
cocaine in vitro, and is 3-10 times more potent of locomotor stimulant than mephedrone or
methylone (Eshelman et al., 2013; Baumann et al., 2014). MDPV is the most common
compound found in the blood and urine of overdose victims, and it would not be
unreasonable to assume this stems from MDPV’s higher selectivity and toxicity. MDMA
demonstrates nonlinear kinetics in rodents and humans, a process in which autoinhibition
of its own metabolization causes higher and more sustaining blood plasma concentrations
than predicted. MDPV is metabolized similarly to MDMA because of the similarities in
structure and may follow nonlinear kinetics as well. Furthering this problem, some of
MDPV’s metabolites are also potent blockers at DAT lengthening action at the transporter
even longer (Baumann et al., 2014). Methylone and MDPV are both self-administered in
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laboratory rat models, but MDPV alone displays escalation of drug intake making its
liability for abuse even higher than the other bath salt compounds (Baumann et al., 2014).
The four cathinone compounds listed above (methcathinone [MCAT], mephedrone
[4-CH3 MCAT], methylone, and MDPV) have either been assigned Schedule I status by the
US Drug Enforcement Agency or are on temporary Schedule I status pending further
evaluation. Recently, another para-substituted MCAT analogue flephedrone, or 4-F MCAT,
has been given temporary Schedule I status due to its consistent presence in bath salts.
Methedrone, or 4-OCH3 MCAT, has not yet been scheduled but has begun appearing in
drugs as well (Bonano et al., 2014). Preliminary data show varying potencies and efficacies
at DAT and SERT for these compounds, each of which differ from MCAT by just one
substituent on the benzyl ring. These variations suggest that para-substituted MCAT
analogues might be a way for drug chemists to avoid DEA scheduled illegal compounds, but
produce a compound with similar effects. Studying multiple MCAT analogue compounds
with altered substituent groups could identify new drugs of abuse, and the structural
elements interacting with transporters that cause behavioral and neurochemical effects.
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Figure 1.8 (borrowed from Baumann, et al., 2014): The chemical structures of the main, or
parent, bath salt compounds are shown. Both mephedrone and methylone have the
identical methcathinone backbone, with a different group attached to the benzyl ring.
MDPV bears the cathinone backbone, but has more complicated substituents attached,
which, most likely, are the reasons for its altered effects at monoamine transporters.
Amphetamine and methamphetamine are also shown for comparison due to similar effects
and mechanisms at transporters.
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Aims of Study

As novel synthetic drug compounds continue to appear in street drug-cocktails, a better
understanding is needed of the human serotonin transporter and how drugs interact with,
modulate, and elicit effects at the transporter. Six new 4-para substituted methcathinone
analogues were tested using a two-electrode voltage clamp oocyte model in order to
illustrate and quantify the differences in potency and efficacy at the transporter caused by
the varying substitutions.
After the raw data for each compound is acquired, the Hill equation can be used to calculate
potency and maximum current. These measurements can then be correlated with other
relevant factors, like electron-withdrawing capacity or lipophilicity, in order to
demonstrate which specific parameters could be influencing potency and efficacy at the
serotonin transporter.
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Materials and Methods
3.1 Experimental Approach

Electrical currents were recorded using TEVC, mediated by hSERT expressed in
Xenopus laevis oocytes. The oocytes were perfused with methcathinone (MCAT),
flephedrone (4-F MCAT), clephedrone (4-Cl MCAT), brephedrone (4-Br MCAT),
mephedrone (4-CH3 MCAT), and methedrone (4-OCH3 MCAT).

3.2 Human Dopamine and Serotonin Transporter RNA

A DNA linearization reaction was performed using hDAT and hSERT DNA (both
amplified by VCU’s DNA Core Facility). Varying amounts of DNA (10 – 30 μg) were added
to Not I restriction enzyme, Buffer 3 (10x), and BSA (100x). The mixture was then diluted
with ddH2O to 30 μL total volume.
The QIAquick PCR Purification Protocol was then used to microcentrifuge the DNA.
We used the Ambion mMessage Machine T7 kit to then transcribe hDAT and hSERT cRNA
in the pOTV, oocyte transcription vector. The hDAT and hSERT RNA was frozen at -80 C
until needed for injection.
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3.3 Expression of Human Transporters in Xenopus Oocytes

Oocytes were harvested from adult Xenopus laevis. Anesthetization by 13% - 17%
tricaine methanesulphonate solution was performed before the ovarian follicles, portions
of the ovaries, were removed through a small incision on the frog’s abdomen. The ovarian
follicles were sliced into pieces and placed for 2 hours at room temperature in Ringer’s
solution with no added calcium, and with 2mg/ml collagenase type 1A. Afterward, the
oocytes were rinsed with Ringer’s and stored at 18 degrees Celsius.
We chose healthy stage V and VI oocytes for cRNA injection within 24 hours of
oocyte harvest. Each oocyte was injected with 23.0 nL, 29.0 nL or 36.7 nL of 1μg μL-1
hSERT cRNA (equivalent to 23ng, 29ng, 36.7ng respectively) using Drummond Scientific
Co.’s Nanoject AutoOocyteInjector. The oocytes incubated at 18 degrees Celsius for 5-10
days in Ringer’s solution supplemented with 5% dialyzed horse serum, 550μg mL-1 sodium
pyruvate, 100μg mL-1 streptomycin, 50μg mL-1 tetracycline.
Most of the setbacks encountered over the past year revolved around the oocytes
and RNA injection. There did not seem to be a specific recipe or set up that guaranteed
expression of hSERT in the oocytes. Each batch of oocytes was injected with a different
amount of RNA; 18, 23, 27, 32, 36, or 41 nano-liters. The hSERT RNA was even diluted both
5 and 10 times before injecting for some hSERT batches. It continually appeared that the
RNA was overly toxic for the oocytes and would kill them prior to transporter expression.
For unknown reasons, oocytes harvested in the summer and fall are not as hardy as those
harvested in the winter. Others in the lab have experienced this trend in the past and it
could have contributed to the stubbornness of the oocytes these past few months.
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Performing more experiments to discern approximate recipes for expression of both
hSERT and hDAT would have been immensely helpful. This would eliminate hours
preparing the TEVC for recording before learning that the cells were not expressing
transporter. These complications limited the amount of time spent collecting data and
prevented the entire data collection of all six compounds at hDAT in the time given.

3.4 Two-electrode Voltage Clamp and Analysis

A Gene Clamp 500 Voltage and Patch Clamp Amplifier and a 16-bit A/D converter
were used as the voltage clamp apparatus in these experiments. Each electrode had a
resistance ranging from 1 to 5 MΩ. We voltage clamped the previously injected oocytes
expressing hDAT or hSERT to approximately -60mV (-55mV to -65mV range) and waited
for a stable baseline to be reached while lightly perfusing buffer. The data was taken at 5
kHz and saved digitally for later analysis using 1 kHz filtering and Clampfit 10.2 software.
Currents, both inward and outward, were compared with holding currents (0 to 100 nA in
oocytes with -20 to -60 mV resting potentials) required for voltage clamp at -60mV.
The program OriginLab Graphing & Analysis was used to generate statistical plots of
the data, apply the Hill or Hill1 equations, and to calculate the Imax and EC50 values.
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3.5 Solutions

The oocyte incubation media consisted of: 96 mM NaCl, 0.6 mM CaCL2, 2 mM KCl, 5
mM MgCl2, 5 mM HEPES, 550 μg mL-1 Na pyruvate, 100 μg mL-1 streptomycin, 50 μg mL-1
tetracycline, and 5% horse serum, adjusted to pH 7.4 using KOH.
The extracellular two-electrode voltage clamp buffer solution consisted of (in mM):
7.5 HEPES, 1.2 Ca2+ gluconate, 120 NaCl, 5.4 K gluconate, and the pH was adjusted to 7.4
with KOH.
The intracellular electrode was filled with 3 M KCl.

3.6 4-para Methcathinone Drug Analogues

Methcathinone (MCAT) and the five analogues used in these experiments were
synthesized in racemic HCL salt form by R. Glennon’s lab at VCU School of Medicine using
formerly published procedures: MCAT (Findlay et al., 1981), 4-F MCAT (Archer, 2009), 4OCH3 MCAT (Lespagnol and Hallot, 1954), 4-Cl MCAT (Trepanier and Sprancmanis, 1964),
4-Br MCAT (Foley and Cozzi, 2003), and 4-CH3 MCAT (McDermott et al., 2011). Each
compound was frozen as a 10 micro-molar solution and diluted to the appropriate
concentrations when necessary for testing.
Six different compounds were tested in total. The first compound was
methcathinone, the parent compound to the others, and also known by the names
ephedrone or α-methylamino-propiophenone. Each of the other four analogues has a
substituent group replacing methcathinone’s hydrogen at the 4-para position on the benzyl
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ring. The substituent group is often labeled as ‘R’ when comparing to methcathinone, as in
4-R MCAT. The second compound tested was 4-F MCAT, also known as flephedrone (4fluoromethcathinone). Third and fourth compounds tested were 4-Cl MCAT, or
clephedrone (4-chloromethcathinone), and 4-Br MCAT or brephedrone (4bromomethcathinone). The final two compounds have a methyl group and a methoxy
group attached at the 4-para position; fifth is 4-CH3 MCAT, or mephedrone (4-methyl
methcathinone), and the sixth compound is 4-OCH3 MCAT, or methedrone (paramethoxymethcathinone). During testing and analysis each drug was labeled with its
synthesizers initials and date, so that no bias could be introduced from previously
conceived notions about the compounds.
Methcathinone was placed on the United State’s federal ‘Schedule I Controlled
Substances’ list in 1994 making it illegal and a felony to possess without permission for
research. Flephedrone is currently a member of the United States’ temporary Schedule 1
controlled substances list and is illegal in many other countries. Clephedrone is currently
illegal in Germany, Sweden, and China but has yet to be specifically banned in the US.
Brephedrone and methedrone have been outlawed in China, and mephedrone has been
forbidden in many countries outside the US where the substance has repeatedly been
found in recreational drugs. In 1986 the United States Congress passed the Federal
Analogue Act as a part of the Controlled Substances Act. The analogue act made chemicals
“substantially similar” to those compounds listed as schedule 1 or schedule 2 illegal as well,
if intended for human consumption. For clarification, schedule 1 drugs are those that have
a high potential for abuse, have not been approved for use in medical treatment, possess a
lack of safety even under medical supervision, and have a high probability of psychological
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and physical dependence. Schedule 2 drugs have a high potential for abuse, can cause
severe psychological or physical dependence, but have currently accepted medical use with
great restriction (dea.gov). The chemical structure of all six compounds tested can be seen
on the next page with their corresponding most common names.
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R = substituent group

-

H
methcathinone
F
flephedrone
Cl
clephedrone
Br
brophedrone
CH3
mephedrone
OCH3
methedrone

Figure 3.1 : Structure of Methcathinone and Analogues (borrowed from Bonano et al.,
2014). The backbone structure of methcathinone with the letter “R” representing the
placement of 4-para substituent groups. Beneath the structure, the six different substituent
groups are listed along with the common names for each. Each of the compounds can be
written as 4-R MCAT instead of their common name. These compounds also can be written
by describing the functional group makeup of the compound (ex: α-methylaminopropiophenone is another way of saying methcathinone), though for simplicity those
names are not listed here.
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Results

4.1 Two-electrode Voltage Clamp Recordings

Xenopus oocytes vary in their ability to express human RNA and in the amount of
time that is required. Oocytes express the serotonin transporter (SERT) much faster than
the dopamine transporter (DAT). Data was often collected within a week of injecting RNA
into the oocyte, and in some cases in as little as 3 days post injection. It appeared as though
the RNA was toxic for the cells after most injections. The injected cells declined in health
and died much quicker than control cells injected with water, and quicker than controls
that were not injected. The toxicity-caused-death often forced TEVC recordings into a very
small window between the time the cells begin expressing the transporter and when the
cell membrane begins breaking down and cannot hold a current to collect TEVC data.
Data collection for each drug was also complicated by the presence of a residual
“shelf” most often seen in higher drug concentrations. When a shelf is present, the oocyte
can no longer be used for recording because the transporter is saturated, or forced to
remain open by the drug, and therefore depolarizes the resting current. The oocyte must
be discarded after one reading and replaced with another oocyte because the oocyte will
not return to a normal baseline.
Ideal voltage clamp command potential for oocytes is -60mV, about -10mV less than
the resting membrane potential of neural cells in the human body. When testing, a range
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from -55 to -65 was accepted. Generally, all data for each drug on a given transporter was
collected the same day to prevent discrepancies due to health of the oocyte or differing
batches of expressing injected oocytes. Example recordings from the different compounds
can be seen on pages 42 and 43.
A 5µM concentration of 5-HT or DA is most commonly used as a baseline response
concentration in two-electrode voltage clamp. At concentrations over 5µM, the overall
response can begin to decline. This occurrence is believed to be caused by overcompetition at the transporter pore, slowing down the amount of substrate and ions
traveling through and decreasing the total inward current (Mager et al., 1994). The first
recording (Fig. 4.1 A) of [10µM] methcathinone shows the smallest response of the six
recordings by far, with an average response at 33.3% with [10µM]. The second recording
(Fig. 4.1 B) displays flephedrone at 10µM perfusion concentration. Flephedrone’s average
response at this concentration is the second lowest at 61.2% average relative response for
6 recordings. Clephedrone (Fig. 4.1 E) has the third lowest average at 95.5% relative
response for [10µM]. Mephedrone (Fig. 4.1 F) is fourth with an average relative response
at 110.1% for 10µM concentration. Brephedrone (Fig. 4.1 C) displays the second highest
response, with 112.9% relative response average at [10µM]. Methedrone (Fig. 4.1 D)
clearly possesses the largest response at [10µM] with 155% shown and 142.6% average
compared to the 5µM 5-HT standard.
The only compound that does not demonstrate a shelf, or potential for a shelf, after
perfusion at [10µM] is methcathinone (Fig. 4.1 A). All five methcathinone analogues tested
(Fig. 4.1 B-F) show a shelf after perfusion, though flephedrone and mephedrone appear to
trend back towards the original baseline much faster than the other 3 analogues.
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More data would be needed to quantify each compound’s shelf. Therefore, it is impossible
to speculate at this time as to which compound creates the largest shelf and greatest time
differential before returning to baseline. It is important to note that the relative responses
are given because each recording was taken using a different oocyte having an individually
distinct inward current when perfused with 5µM 5-HT. So while the recordings in figure
4.1 are lined up next to each other, simply comparing them by eye is not sufficient because
there is not a standard response to 5µM 5-HT perfusion. It is also worth noting that the
recordings did not follow a set time frame. Some oocytes take longer than others to
establish a baseline current, and therefore the amount of time before 5µM 5-HT perfusion
and before drug perfusion varies for each oocyte.
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Figure 4.1 : Two-electrode voltage clamp recordings. A: Methcathinone recording at 10µM
concentration, small relative response of 32% with no shelf present. B: Flephedrone
recording at 10µM concentration, relative response of 93% with shelf present. C:
Brephedrone recording at 10µM concentration, large relative response of 119% and large
shelf present. D: Methedrone recording at 10µM concentration, large relative response of
155% and very large shelf present post brephedrone perfusion. E: Clephedrone recording
at 10µM concentration, relative response of 92% with large shelf shown. F: Mephedrone
recording at 10µM concentration, 94% relative response with smaller shelf slowly trending
back toward the original baseline. Each arrow demarcates where resulting currents were
measured.
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4.2 OriginLab – Data Analysis and Graphics

After the two-electrode voltage clamp recordings were taken, the baseline of each
graph was adjusted with the ClampFit program, if need be. When collecting the data, the
sampling rate was 10kHz at an interval of 100 micro-seconds. This large amount of data
was reduced by a factor of 100 and the substituted average gave the graphs shown in the
previous section. After reduction and a change in baseline, the [5µM] 5-HT response was
calculated from the baseline, or the point at which 5-HT was given, to the bottom of the 5HT inward current. These nano-amp inward currents ranged in value and did not always
reach a steady maximum depression. When there was not an obvious maximum
depression, the nano-amp difference was calculated from baseline to the most consistent
point in the bottom of the depression. The amount of inward current caused by the
synthetic cathinone compounds was calculated using the same technique – from the
baseline point where drug was given to the most consistent point at the bottom of the
inward current. At least three calculations were taken for each drug concentration, each
from a different oocyte. For most concentrations, between five and ten points were used.
The calculations were entered into Microsoft Excel and a relative response was calculated
by dividing the total nano-amps of drug response by the total nano-amps of 5-HT response.
The calculation of relative response was required because different oocytes were used for
each data point. An average of the relative responses was then calculated for each drug
concentration, along with a standard deviation and standard error about the mean. For
clarification, an example of Excel data entry and calculations can be seen in Table 4.2 on the
following page.
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Table 4.2 : Example of data entered into excel and calculations performed for each
concentration of all six drug compounds. Here, example data is shown for six different
TEVC calculations, all at 0.1µM concentration of flephedone (FTS-024) with their average
and standard deviation (standard error about the mean not shown). Below that data, the
averages for each flephedrone concentration multiplied by 100 and standard deviations
multiplied by 100 are displayed (other data for flephedrone used to calculate averages not
shown). The values are multiplied by 100 in order to be used as a percentage when
plotting the data later in Origin.

45

The calculations of average and standard deviation (x100) for each concentration
were entered into OriginLab Data Analysis program. Using this program, plots were
created for each drug based on the averages and deviations. After plotting the points, the
Hill equation was fitted to the plot, and the Hill equation calculated a Imax and a EC50 for
each drug compound. These plots begin on the following page.
The Hill equation was developed by Archibald Hill in 1910 to quantify cooperative
binding, originally to describe oxygen bound to hemoglobin. Cooperative binding is the
variability (or affinity) of specific ligand binding due to the presence, or lack of, other
ligands already being bound at additional sites. This is also known as allosteric control.
The Hill equation is a transformation of a logistic function and the Hill equation written as a
rational function for allosteric affinity calculations is:
I = ( Imax[S]n ) / ( Kn + [S] )
where I is the reaction velocity, Imax is maximum reaction velocity, [S] is substrate
concentration, K is analogous to Michaelis constant (Km) or EC50, and n is the Hill coefficient
– representing the degree of coopertivity. When the Hill coefficient equals 1, there is not
allosteric affinity and binding of the ligand is completely independent. When the Hill
coefficient is less than 1, this indicates negatively cooperative binding, which follows
Michaelis-Menten kinetics and a hyperbolic plot. Positively cooperative binding occurs
when the Hill coefficient exceeds 1 and follows a sigmoidal shape when plotting velocity
and substrate concentration (The Biology Project, 2007).
OriginLab also offers a variation of the Hill equation, the Hill1, an offset version.
Hill1 was used for 5 of 6 plots because it gave more accurate fits with the data. The Hill1
equation is:

y = [ START + (END – START) ] [ ( xn ) / ( kn + xn ) ]
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Figure 4.3 : Plot of Methcathinone’s (MCAT) average relative responses at the human
serotonin transporter, including error, as compared to the [5µM] 5-HT standard. Data
gathered at 0.1, 0.5, 1.0, 5.0, 10.0, 30.0, 50.0, and 100.0µM-drug concentrations. A Hill1 Fit
line is shown. Imax = 98.44% (+/- 6.37), EC50 = 15.73µM (+/- 3.05).
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Figure 4.4 : Plot of Flephedrone’s (4-F MCAT) average relative responses at the human
serotonin transporter, including error, as compared to the [5µM] 5-HT standard. Data
gathered at 0.1, 0.3, 1.0, 3.0, 10.0, and 30.0µM-drug concentrations. A Hill1 Fit line is
shown. Imax = 84.55% (+/- 7.48), EC50 = 4.67µM (+/- 1.36).
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Figure 4.5 : Plot of Brephedrone’s (4-Br MCAT) average relative responses at the human
serotonin transporter, including error, as compared to the [5µM] 5-HT standard. Data
gathered at 0.1, 0.3, 1.0, 3.0, 10.0, and 30.0µM-drug concentrations. A Hill Fit line is shown.
Imax = 103.37% (+/- 0.57), EC50 = 0.52µM (+/- 0.01).
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Figure 4.6 : Plot of Methedrone’s (4-OCH3 MCAT) average relative responses at the human
serotonin transporter, including error, as compared to the [5µM] 5-HT standard. Data
gathered at 0.1, 0.5, 1.0, 5.0, 10.0, and 50.0µM-drug concentrations. A Hill1 Fit line is
shown. Imax = 203.39% (+/- 20.15), EC50 = 5.56µM (+/- 1.33).
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Figure 4.7 : Plot of Clephedrone’s (4-Cl MCAT) average relative responses at the human
serotonin transporter, including error, as compared to the [5µM] 5-HT standard. Data
gathered at 0.1, 0.5, 1.0, 5.0, 10.0, and 50.0µM-drug concentrations. A Hill Fit line is shown.
Imax = 108.46% (+/- 8.39), EC50 = 1.28µM (+/- 0.33).
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Figure 4.8 : Plot of Mephedrone’s (4-CH3 MCAT) average relative responses at the human
serotonin transporter, including error, as compared to the [5µM] 5-HT standard. Data
gathered at 0.1, 0.5, 1.0, 5.0, 10.0, and 50.0µM-drug concentrations. A Hill1 Fit line is
shown. Imax = 112.12% (+/- 4.34), EC50 = 1.20µM (+/- 0.128).
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4.3 Comparisons of Compounds

The plots shown of hSERT’s response to each of the six compounds (seen on the last
few pages) as compared to [5µM] 5-HT can be combined into one plot – Figure 4.9. In the
Hill equation, Imax refers to the maximum current of the reaction. In other words, Imax is a
measurement of how fast or efficient each drug compound can pass through the
transporter alongside ions causing the inward currents seen in TEVC. Methedrone has the
highest Imax by far, followed by the Imax of every other compound at about half methedrone.
Exact values of Imax can be compared in Table 4.10 on the next page and in Figure 4.11 on
the following page.
It is impossible to distinguish the EC50 values from the plot alone. The EC50 is the K
value in the Hill equation and is also synonymous with KM. The EC50 gives the effective
concentration at which you reach 50% of Imax. In other words, it is half Imax or a measure of
each compounds’ potency. Brephedrone is the most potent compound with a EC50 of 0.52
followed by mephedrone at EC50 = 1.20. This means that for these two compounds, a
0.52µM concentration and a 1.20µM concentration cause 50% of their overall effect,
respectively. Clephedrone is the third most potent with EC50 = 1.29, followed by
flephedrone (EC50 = 4.67), methedrone (EC50 = 5.56), and finally methcathinone (EC50 =
15.73). These exact EC50 values can be compared in Table 4.10, on the following page in
bar graph form on Figure 4.12, and as a scatter plot in Figure 4.13.
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Figure 4.9 : Hill equation plots of all 6 compounds with the Hill coefficients shown in
parentheses.

DRUG
Imax
Imax error
EC50 error
EC50
Brephedrone
103.37
0.57
0.52
0.01
Mephedrone
112.12
4.34
1.2
0.128
Clephedrone
108.46
8.39
1.29
0.33
Flephedrone
84.55
7.48
4.67
1.36
Methedrone
203.39
20.15
5.56
1.33
Methcathinone
98.44
6.37
15.73
3.05
Table 4.10 : Imax (% of [5µM] 5-HT response) and EC50 (µM) for all five 4-para MCAT
analogues and methcathinone. Compounds listed in order of potency. All errors are
standard deviations from the mean.
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Figure 4.11 : Bar graph representation of Imax for all 6 compounds.

Figure 4.12 : Bar graph representation of EC50 for all 6 compounds.
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Figure 4.13: A normalized graph of all six Hill equation fits, making EC50 for each
compound at SERT easier to visually determine. Where each line falls on the X axis, at Y
value = 0.5, equals the EC50. The smaller the EC50 value, the more potent the compound. So,
for example, brephedrone’s X value at Y=0.5 is smaller than clephedrone’s making
brephedrone the more potent compound. Hill equation coefficients are shown for each
compound in parentheses.
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4.4 Correlational Comparisons

The EC50 values calculated from concentration-effect curves in oocytes for each drug
compound were first correlated with the nanomolar in-vitro release EC50 values from
Bonano et al., 2014 and Baumann et al., 2012. The results were statistically significant,
with the p value equaling 0.039 and the r value equaling 0.83, indicating a predictive
relationship between the two. The correlational results can be seen in Figure 4.15.
Next, the EC50 oocyte values and their respective cubic angstrom volume amounts
were compared. The resulting correlation gave a weak correlation between the two (p =
0.0026, r = -0.56), mainly due to the outlier methedrone (4-OCH3 MCAT). When
methedrone was excluded, it resulted in a strong correlation between the EC50 values and
volume (p = 0.0005, r = -0.992). The results with the outlier can be seen in Figure 4.16 and
the correlation without methedrone are seen in Figure 4.17.
After the previous correlations suggested that methedrone is an outlier, other
correlations were performed to search for a possible explanation. First, the EC50 values
were correlated with Taft’s Steric Parameter (listed in Table 4.14), or a measure of overall
steric bulk, different from the cubic angstrom values of volume used previously. This
resulted in a strong and statistically significant correlation (p = 0.003, r = 0.95) and can be
seen in Figure 4.18.
Next, the EC50 values from oocytes were correlated with the corresponding values
for each 4-para substitution’s electron withdrawing capacity. These values can be found in
Table 4.14. The results from this correlation were statistically insignificant (p = 0.377, r = 0.445) and can be seen in Figure 4.19.
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Values of lipophilicity for each compound were correlated with their EC50 values
obtained from oocyte concentration-effect curves. The results were statistically significant
with p = 0.004 and r = -0.933. The lipophilicity values for each compound can be found in
Table 4.14 and the correlation results can be seen in Figure 4.20.
The measurements of volume do not correlate strongly with the corresponding
Taft’s E values, as can be seen in Figure 4.21. The correlation resulted in r = -0.65 and p =
0.16. Once again, methedrone (4-OCH3 MCAT) appeared to be an outlier so the correlation
was performed again without methedrone. The results were statistically significant (r =
-0.97, p = 0.005) and can be seen in Figure 4.21 as well.
Unlike the EC50 values obtained from oocyte concentration curves, the EC50 values
from Baumann et al. (2012) correlate strongly with Taft’s E and measures of volume. The
results for EC50 values in synaptosomes correlated with Taft’s E are shown in Figure 4.22 (r
= 0.88, p = 0.02) and the results for EC50 values in synaptosomes correlated with volume
can be found in Figure 4.23 (r = -0.92, p = 0.008). All the values used can be seen in Table
4.14.
Lastly, the EC50 values from oocyte concentration curves were correlated with both
substituent length and maximum width of the substituent. Both returned statistically
insignificant correlations when methedrone (4-OCH3 MCAT) was included. EC50 values
correlated with length are shown in Figure 4.24 (r = -0.61, p = 0.19) and EC50 values
correlated with maximum width are shown in Figure 4.26 (r = -0.32, p = 0.54). When
methedrone was excluded, both returned strong and statistically significant correlations.
Figure 4.25 displays the correlation between EC50 values and substituent length, without
methdrone (r = -0.96, p = 0.01). The correlation between EC50 values and substituent
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maximum width, excluding methedrone, can be seen in Figure 4.27 (r = -0.95, p = 0.01).
The values for substituent length and width were borrowed from the Sakloth et al. (2014)
paper and can be found below in Table 4.14.

Table 4.14: Values used in each correlational comparison. The EC50 values in oocytes are
measured in micromolar amounts. EC50 values in synaptosomes are nanomolar (Bonano et
al., 2014, Baumann et al., 2012) and volume is cubic angstroms (Sakloth, et al. 2015). Taft’s
values are a measure of functional steric bulk, EWC is short for ‘electron-withdrawing
capacity’, and the lipophilicity of each compound is also shown.. (Sakloth, et al. 2015).
Physochemical parameters (Taft’s, EWC, Lipophilicity) borrowed from Wolff, 1980. Finally,
the length of substituent (Å), and maximum width of substituent (Å) for each compound
are also listed (Sakloth, et al. 2015).
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Figure 4.15: LogEC50 values from concentration-effect curves in oocytes correlated with
the logEC50 values from Bonano et al., 2014 and Baumann et al., 2012, found in Table 4.14.
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Figure 4.16: Correlational analysis of EC50 values obtained from oocyte concentrationeffect curves including methedrone (4-OCH3 MCAT). Results are statistically significant but
with a very weak correlation. Volume values for each compound can be found in Table
4.14.
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Figure 4.17: Correlational analysis of EC50 values obtained from oocyte concentrationeffect curves and respective values of volume for each compound, excluding methedrone
(4-OCH3 MCAT) shown here in red. Results are statistically significant, with a very strong
correlation suggesting that methedrone is an outlier. Volume values for each compound
can be found in Table 4.14.
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Figure 4.18: Correlational analysis of EC50 values obtained from oocyte concentrationeffect curves and Taft’s Steric E values, or a measure functional steric bulk. Taft’s values for
each compound can be found in Table 4.14.
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Figure 4.19: Correlational analysis of EC50 values obtained from oocyte concentrationeffect curves and Electron-Withdrawing Capacity (EWC) values. EWC values for each
compound can be found in Table 4.14. This correlation is statistically insignificant, but if
we exclude 4-CH3 MCAT and 4-OCH3 MCAT then the results are statistically significant (r = 0.96, p = 0.04).
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Figure 4.20: Correlational analysis of EC50 values obtained from oocyte concentrationeffect curves and lipophilicity values. Lipophilicity values for each compound can be found
in Table 4.14.
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Figure 4.21: Correlation between Taft’s Steric E and the volume of each methcathinone
analog. All values can be found in Table 4.14. The correlation between Taft’s and Volume
is weak and statistically insignificant, r = =0.65 and p = -0.16. When methedrone (4-OCH3
MCAT) is excluded, r = -0.97 and p = 0.005, suggesting that particular point is an outlier.
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Figure 4.22: Correlational analysis between all six EC50 values in synaptosomes (Baumann
et al., 2012) and Taft’s Steric E (Bonano et al., 2014). The result is statistically significant,
with an r value of 0.88 and a p value of 0.02. All values can be found in Table 4.14.
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Figure 4.23: Correlational analysis between all six EC50 values in synaptosomes (Baumann
et al., 2012) and the volume of each corresponding compound. The correlation is
statistically significant, r = -0.92 and p = 0.008. All the values can be found in Table 4.14.
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Figure 4.24: The EC50 values from concentration curves in oocytes correlated with the
length of each substituent, in angstroms. The substituent length values can be found, along
with the EC50 values, in Table 4.14. The correlation gave a statistically insignificant result, r
= -0.61 and p = 0.19.
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Figure 4.25: Excluding methedrone (4-OCH3 MCAT), the EC50 values from concentration
curves in oocytes correlated with the length of each substituent. The substituent length
values can be found, along with the EC50 values, in Table 4.14. Unlike the previous
correlation (with methedrone included), the results were statistically significant – r = -0.96
and p = 0.01.
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Figure 4.26: The EC50 values from concentration curves in oocytes correlated with each
substituent’s width, in angstroms. The results are statistically insignificant, r = -0.32 and
p = 0.54. All values can be found in Table 4.14.
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Figure 4.27: Correlational statistics between the EC50 values from concentration curves in
oocytes and the width of each substituent, excluding methedrone (shown in red). The
results of this correlation are statistically significant after excluding the methedrone outlier
point (r = -0.95, p = 0.01).
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Table 4.28 : A summary of all correlational analyses performed. Results are listed here
including the exact R and P values. Visual representations of each correlation can be found
in Figures 4.15 – 4.27.
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Discussion

Two different variations of the Hill equation were used to calculate maximum
currents and EC50 values for the six 4-para substituted methcathinone compounds. The
‘Hill’ equation was fitted to flephedrone (4-F MCAT), brephedrone (4-Br MCAT), and
clephedrone while the ‘Hill1’ equation was used for methcathinone (MCAT), methedrone
(4-OCH3 MCAT), and mephedrone (4-CH3 MCAT). The Hill1 equation includes an offset and
was used when the lowest concentration of each compound (0.1 micromolar) recorded was
significantly greater than zero. Flephedrone, brephedrone, and clephedrone either elicited
no response at the 0.1 micromolar concentration, or were trending toward zero and the
Hill1 offset was not needed. Methcathinone required more data points for a proper Hill
equation fit due to its high EC50 value. Recordings were taken at 0.1, 0.5, 1.0. 5.0, 10.0, 30.0,
50.0, and 100.0µM-drug concentrations for methcathinone.
Five of the six compounds were found to have reasonably similar maximum
currents (between 84-113 nano-amps), while methedrone (4-OCH3 MCAT) had a maximum
current of 203.39 nano-amps. The much larger maximum current suggests that
methedrone is much more efficacious at hSERT than the other compounds. In other words,
methedrone is much better at opening the transporter and allowing current to flow thru
regardless of potency at the transporter. The vast difference in maximal current adjusts
methedrone’s EC50 to the right on the graph – or makes it larger than expected. Baumann
et al. (2012) and Bonano et al. (2014) simply looked at total release of serotonin in
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synaptosomes caused by each compound. Methcathinone might have caused total release
much quicker than the other compounds, but their experimental set up did not take into
account the differences in time of release and efficacy of the compounds. This could
possibly explain methcathinone’s lack of correlation between oocyte and synaptosome data
(seen in Figure 4.15). Methcathinone’s degree of efficacy at the serotonin transporter could
also have other effects, if repeatable in vivo. Is it possible that methcathinone might
activate other transporters or channels as well due to its high degree of efficacy. For
instance, the amount of current caused my methedrone acting on the serotonin transporter
could be enough to activate surrounding calcium channels. Methedrone’s effects at other
related transporters would be an interesting continuation of this project, due to its high
efficacy and possible potential for toxicity.
Each of the six compounds considered in this thesis produced concentrationdependent effects at hSERT. Brephedrone was shown to be the most potent compound
eliciting effects on the serotonin transporter followed by (in order of potency)
mephedrone, clephedrone, flephedrone, methedrone, and methcathinone. The Bonano et
al. (2015) paper suggested that the larger the Taft’s Steric E (ES value), the more potent a
compound would be for DAT instead of SERT. In other words, the ES value is inversely
related to the amount of steric bulk, and the lower the ES value, the more potent the
compound should be at hSERT. The SERT EC50 values in oocytes calculated from the data
acquired for this thesis (Table 4.10) somewhat agree with the Bonano et al. paper.
Methcathinone has the smallest functional steric bulk of the six compounds (ES = 1.24),
should be the most selective at DAT, and clearly is the least potent at SERT with a EC50 of
15.73. Methedrone (4-OCH3 MCAT) appears to be the next least potent at SERT in our data
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(EC50 = 5.56) and this almost agrees with the ES value (0.69) where methedrone is the third
highest. Bonano et al. found methedrone to be an outlier, having the most selectivity at
SERT. The data here does not agree with Bonano et al.’s calculations of methedrone, and
comes closer to following the predictions made from ES values. Based on these ES value
predictions, flephedrone (4-F MCAT, ES = 0.78) should be the second least potent at SERT
behind methcathinone, but our data suggest that flephedrone (EC50 = 4.67,) is third least
potent. Clephedrone (4-Cl MCAT, ES = 0.27) has the next lowest ES value, Bonano et al.
calculated it to be the next highest in SERT selectivity, and our data (EC50 value of 1.29 [+/0.33]) agree. Mephedrone (4-CH3 MCAT, ES = 0) was found to be the second most potent
compound at SERT in both data sets (EC50 = 1.20). Bonano et al. found brephedrone (4-Br
MCAT) to be the most potent compound at SERT, while having the second lowest ES value
(0.08). Our data from oocyte concentration curves agrees with the Bonano et al. paper in
that brephedrone (EC50 = 0.52) is the most potent compound at the hSERT transporter. In
summary, the data collected for this thesis mostly agrees with Bonano et al. prediction that
as the substituent’s ES value gets smaller the compound becomes more SERT selective.
Correlational statistical experiments were employed using the new EC50 values from
the concentration-effect curves in oocytes. First, the new EC50 values from oocytes were
calculated with the EC50 values from synaptosomes in Bonano et al. (2014) and Baumann et
al. (2012) (all values can be found in Table 4.14). This resulted in a significant correlation
between the two sets of EC50 values (p = 0.039, r = 0.83) suggesting that the concentration
effect curve for each compound is similar in both xenopus oocytes and synaptosomes, and
can be seen in Figure 4.15.
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Next, a correlational analysis was performed between EC50 values from oocytes and
a measure of volume for each 4-para substituted compound. These values of volume in
cubic angstroms were borrowed from Sakloth, et al. 2015 and can also be found in Table
4.14. The correlation between volume and oocyte EC50 values is very weak but statistically
significant with a p value of 0.0026 and an r value of -0.56, shown in Figure 4.16. When
volume and EC50 values are plotted, like in Figure 4.16, it is obvious that one point is an
outlier compared to the others. That data point is methedrone (4-OCH3 MCAT), with the
second highest EC50 value of 5.56 micromoles and the second lowest volume of 153.78
cubic angstroms. Another correlation was performed without methedrone’s data point and
the results differed drastically. Without methedrone, p = 0.0005 and r = 0.992, and can be
seen in Figure 4.17. The stark contrast between the correlations of volume and EC50 values,
with and without the methedrone data point, suggest that it could be an outlier. A
correlation between volume and Taft’s E (Figure 4.21) supports this theory because
methedrone appears to be an outlier here as well. In order to explore why methedrone
might be acting in such a way, the EC50 values were next correlated with the three
parameters from Bonano et al. (2014): Taft’s steric parameter, electron-withdrawing
capacity, and lipophilicity.
Bonano et al. previously hypothesized that MCAT analogues with para substituents
would demonstrate selectivity for either DAT or SERT, depending on the substituent
(Bonano et al., 2015). In Bonano et al.’s paper, the only statistically significant correlation
was found between selectivity at the transporters (or EC50 value) and functional steric bulk.
To quantify steric bulk, Bonano et al. used Taft’s steric parameter (ES) which is calculated
based on both steric strain and steric hindrance of each compound, as well as inductive,
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resonance, and field influences (Bonano et al., 2015). ES values are indirectly related to the
amount of functional steric bulk. In other words, the higher the ES value, the lower the
functional steric bulk of the substituent. The calculated ES values can be found in Table
4.14. A correlation between the ES values and the EC50 values produced an r value of 0.96
and a p value of 0.003, and can be seen in Figure 4.18. This is a strong correlational r value,
and a p value less than 0.05, indicating a statistically significant correlation. It is interesting
that the EC50 values in oocytes correlate well with the experimental Taft’s E value but not
volume, while the EC50 values from synaptosomes correlate with both.
The cause for methedrone (4-OCH3 MCAT) being an outlier in the EC50 versus
volume plot could potentially be caused by electronic factors of the substituent group. To
explore this possibility, a correlation was performed between EC50 values and the electronwithdrawing capacity of each 4-para substituent compound. Methedrone possesses the
lowest electron-withdrawing capacity (EWC = -0.27) and all the electron-withdrawing
values can be found in Table 4.14. The correlation experiment returned a weak r value of
-0.445 and a high p value of 0.377. These results, shown in Figure 4.19, suggest that
electron-withdrawing capacity is not the cause of methedrone’s aberrant placement on the
EC50 vs. volume plot and methedrone’s strangely weak potency at the serotonin
transporter.
The relationship between the EC50 value of each compound and lipophilicity was
correlated and the resulting values, r = -0.933 and p = 0.004, propose a significant
statistical relationship between the lipophilcity and the EC50 value of each compound.
Figure 4.20 illustrates the correlation and suggests that the liophilicity of each 4-para
substituted methcathinone compound could influence the respective EC50 values.
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The EC50 values obtained by Baumann et al. (2012) in synaptosomes correlate
strongly with both Taft’s E (Figure 4.22, r = 0.88, p = 0.02) and volume (Figure 4.23, r = 0.92, p = 0.008). The EC50 values from oocytes correlate with EC50 values from
synaptosomes, but not with volume and Taft’s E signifying a difference modulating EC50
values in oocytes that does not exist in synaptosomes. Oocyte EC50 values have been shown
to correlate well with values of substituent length and width, (Figures 4.25, 4.27) similar to
synaptosomes when excluding methedrone. Thus the discrepancies in EC50 values between
synaptosomes and oocytes could be caused by a difference in expression, protein
packaging, or modification and previous experiments have shown differing EC50 values in
Xenopus oocytes when compared to values in rat syaptosomes (Dowd et al. 1996).
In conclusion, each of the six 4-para substituted methcathinone compounds elicit a
distinct response at the human serotonin transporter. The particular substitution made at
the 4-position on the benzyl ring influences the overall potency at the serotonin
transporter, and the size of the substitution clearly is a factor. Substituent volume does not
correlate perfectly though, as shown by the outlier methedrone (4-OCH3 MCAT). The
experimental measurement of Taft’s E, which takes into account volume, is more predictive
of methcathinone analog efficicay at hSERT and the data suggest other factors are also at
play. Electron-withdrawing capacity was shown to have no direct influence on efficacy and
EC50 values. However, the lipophilicity of each compound provided a significant correlation
to the EC50 values found from oocyte concentration-curves. These results imply the general
rule: the larger the overall volume of the compound, the more efficient that compound will
be at the serotonin transporter (compared to the dopamine transporter), when expressed
in oocytes. Outliers are possible due to other factors including lipophilicity (and excluding
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steric bulk and electron-withdrawing capacity) and the results differ in other assays such
as rat synaptosome experiments. Such dissimilarities could be due to varying membrane
lipid and protein compositions in the different cell types or any number of pre or posttranslational modifications to the transporter. We can conclude that measurements of
volume, substituent size, and steric bulk are indirectly related to methcathinone analogue
potency at the human serotonin transporter, possibly modulated in part by the compound’s
lipophilicity and other unknown factors.
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